VELAGLUCERASE FOR TREATING TYPE III GAUCHER DISEASE

• 1. 磺酰胺酶(SGSH)变体、载体、组合物以及用于治疗IIIA型粘多糖病(MPS IIIA)的方法和用途 [P] . 中国专利： CN110809626A . 2020-02-18
• 2. 用于治疗肥厚型心肌病的III 型磷酸二酯酶(PPE III)抑制剂或Ca [P] . 中国专利： CN102223882B . 2016.02.03
• 3. PHARMACEUTICAL COMPOSITION CONTAINING RESVERATROL FOR TREATING TYPE II AND TYPE III GAUCHER DISEASES [P] . 韩国专利： KR20160101452A . 2016-08-25

  机译： 含白藜芦醇的药物组合物，用于治疗II型和III型糖尿病患者

• 4. COMPOSITIONS AND METHODS FOR TREATING TYPE III GAUCHER DISEASE [P] . 韩国专利： KR102096752B1 . 2020-04-02

  机译： 治疗III型糖尿病疾病的组合物和方法

• 5. COMPOSITIONS AND METHODS FOR TREATING TYPE III GAUCHER DISEASE [P] . 韩国专利： KR20190121400A . 2019-10-25

  机译： 治疗III型糖尿病疾病的组合物和方法

• 1. Mechanisms of Huanglian Jiedu Decoction in treating coronary heart disease and type 2 diabetes mellitus based on network pharmacology [J] . Ji-Lin Fan, Ting-Ting Zhu, Xiao-Ling Tian, 海南医科大学学报（英文版） . 2021,第015期
• 2. Mechanisms of Huanglian Jiedu Decoction in treating coronary heart disease and type 2 diabetes mellitus based on network pharmacology [J] . Ji-Lin Fan, Ting-Ting Zhu, Xiao-Ling Tian, 海南医科大学学报(英文版) . 2021,第015期
• 3. Qiming granule in treating type 2 diabetic kidney disease patients:study protocol for a randomized controlled trial [J] . Jian Huo, Jun-Guo Duan, Xue-Jing Lu, 传统医学研究（英文版） . 2021,第001期
• 4. Clinical characteristics of type III Gaucher disease in children and adolescents enrolled in a trial of velaglucerase alfa [J] . Ben Dridi Marie-Francoise, EI-Beshlawy Amal, Marzouk Iman, Molecular genetics and metabolism . 2015,第2期
• 5. Cholangiocarcinoma occurring in a patient with type 1 Gaucher disease treated with velaglucerase alfa enzyme replacement therapy: First case report [J] . Holubar Jan, Bres Virginie, Costes-Martineau Valerie, Blood cells, molecules and diseases . 2018,第期
• 6. Cholangiocarcinoma occurring in a patient with type 1 Gaucher disease treated with velaglucerase alfa enzyme replacement therapy: First case report [J] . Holubar Jan, Bres Virginie, Costes-Martineau Valerie, Blood cells, molecules and diseases . 2018,第期
• 7. Chapter 7 CFD Reconstruction of Blood Hemodynamic Based on a Self-made Algorithm in Patients with Acute Type IIIb Aortic Dissection Treated with TEVAR Procedure [C] . A. Polanczyk, A. Piechota-Polanczyk, Ch. Neumayer, IUTAM Symposium on Moving Boundary Problems . 2019
• 8. Transition to self-management: Perspectives and experiences of glycogen storage disease type I and type III patients and their parents. [D] . King, Kellie L. 2009
• 9. Safety and efficacy of velaglucerase alfa in Gaucher disease type 1 patients previously treated with imiglucerase [O] . Ari Zimran, Gregory M. Pastores, Anna Tylki-Szymanska, -1
• 10. Long-Term Velaglucerase Alfa Treatment in Children with Gaucher Disease Type 1 Naïve to Enzyme Replacement Therapy or Previously Treated with Imiglucerase [O] . Smith Laurie, Rhead William, Charrow Joel, 2016

• 1. Discussion on the Effectiveness of Elevating HDL-C in Treating Cardiovascular Diseases of Patients with Type 2 Diabetes Mellitus [J] . Shasha Wang ,Liyue Wang . 临床医学国际期刊（英文） . 2019,第4期
• 2. Qiming granule in treating type 2 diabetic kidney disease patients:study protocol for a randomized controlled trial [J] . Jian Huo ,Jun-Guo Duan ,Xue-Jing Lu . 传统医学研究（TMR） . 2021,第001期
• 3. 无机溶胶凝胶法制备B型和M型VO2粉体 [C] . 董琰峰 ,杨修春 ,周石山 . 2010全国玻璃技术交流研讨会 . 2010
• 4. 用于口腔黏膜疾病治疗的盐酸苄达明壳聚糖缓释型粉雾制剂的研究 [A] . 姜旺展 . 2013